Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jul 24, 2021 5:40pm
104 Views
Post# 33601310

RE:RE:RE:RE:RE:RE:Sedar

RE:RE:RE:RE:RE:RE:Sedar There is no new prespectus showing up on the SEC site via Bloomberg yet either. It looks like this has been put together rather hastily. Hopefully, that is not a bad sign but the confluence of the Cantor meetings with US institutions on Thursday and the hasty filing of this ATM late Friday is concerning since it might indicate THTX is once again struggling to do the right thing and walk away from low-ball offers from institutions.

Could it be that I am right in saying that Paul really did not want to partner NASH, got an indication of serious interest from institutions on Thursady and returned to the board and asked to move forward with another low-priced share offering in order to quickly reverse their course on NASH? That could be justified by trying to make the claim that the dilution from an offering would be less than the dilution from a partnership and that might be correct. So such a quick turnabout could make economic sense if that is what they are pursuing. But that would be quite a surprise. 

But the institutions would not likely be as happy with the ATM approach versus a priced deal. So, this is all unlikely. But until the company provides some context we are only left to speculate about what prompted this ATM situation.  

scarlet1967 wrote: I see nothing on the site yet.


<< Previous
Bullboard Posts
Next >>